Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 2020 Discussion: The SCORED Study
Author(s): Harriette Van Spall , Deepak L Bhatt Added: 3 years ago
Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Deepak L Bhatt (Brigham and Women's Hospital, Boston, MA, US) discuss the results and implications of the SCORED trial. Dr Van Spall asks about the change the original endpoints of the trial in light of the evolving knowledge on the SGLT2i class and the impact of the COVID19 pandemic. Dr Bhatt and Dr Van Spall reviews the patient… View more

Prevention & Chronic Conditions
FOURIER-OLE: The Trial in Context
Author(s): Marc S Sabatine Added: 1 year ago
In this video, Dr Marc S Sabatine addresses the context of theFOURIER-OLElong-term trial and how it impacts the current treatment paradigm. It also reports on what impact this extension study has on the guideline directed LDL-C targets and what this means for the use of PCSK-9 inhibitors. This video is part of a series of interviews, recorded at ESC Congress 2022 in Barcelona, in which Dr… View more

Prevention & Chronic Conditions
Author(s): Thomas D Giles Added: 3 years ago
Introduction The concept of 'hypertensionÔÇÖ as a clinical entity has been a work in progress for decades. At some point, the diagnosis of hypertension began to be linked to specific levels of blood pressure. The Joint National Committee (JNCI-JNC7) reports provide a perspective and an understanding that a clearer and precise definition might avoid the dead-end that the current concept of… View more

Prevention & Chronic Conditions
Sergio Baptista
Author of more than 120 scientific communications (of which more than 50 in International Congresses). Author of more than 20 articles published, most in International journals Associate investigator of multiple multicentre clinical trials and national and international registries Assistant of the course of Introduction to the Clinic (3rd year, Faculty of Medicine of Lisbon). Professor and… View more
Author(s): David SH Bell Added: 3 years ago
Thiazolidinediones (TZD) and metformin lower cardiac risk factors, as well as lowering serum glucoses, and are therefore the best choice for initial therapy of type 2 diabetes. To choose between metformin and a thiazolidinedione is difficult because of the many benefits of both drugs. In most cases, a combination of metformin and a TZD is chosen, and this article describes the rationale for this… View more

Prevention & Chronic Conditions
Author(s): David SH Bell Added: 3 years ago
Thiazolidinediones (TZD) and metformin lower cardiac risk factors, as do serum glucoses, and are therefore the best choice for initial therapy of type 2 diabetes. To choose between metformin and a thiazolidinedione is difficult because of the many benefits of both drugs. In most cases, a combination of metformin and a TZD is chosen, and this article describes the rationale for this decision. The… View more

Prevention & Chronic Conditions
Author(s): Christopher J White Added: 3 years ago
More than three-quarters of a million Americans will suffer a stroke this year. Stroke ranks as the third most common cause of death after heart disease and cancer. It is the number one cause of disability among adults and the main reason for rehabilitation. Many, but not all, strokes are related to atherosclerosisÔÇöthe same disease that causes heart attacks. Blockage of one of the two main… View more

Intervention
Sidney C. Smith
Job title: Professor of Medicine, UNC-Chapel Hill (1994-present); Chief, Division of Cardiology, UNC-Chapel Hill (1994-2001)
Dr. Smith is an active clinical cardiologist and clinical researcher. He is a world-recognized expert on developing national and international guidelines for assessment of cardiovascular risk and for treatment of cardiovascular disorders including hypertension, cholesterol abnormalities, and acute coronary syndromes. Dr. Smith is a past president of the American Heart Association and the World… View more
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD
Author(s): Brian Bergmark Added: 1 week ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study… View more

Prevention & Chronic Conditions
ACC 2022: Late-breaking Science Video Collection
Author(s): Justin Ezekowitz , Harriette Van Spall , Dylan L Steen , et al Added: 2 years ago
Our regular review seriesView from the Thoraxcenterhosted by Prof Nicolas Van MieghemandDr Joost Daemen(Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data. For a deeper dive into key clinical trial data,Dr Harriette Van Spall(McMaster University, Hamilton, CA)talks with principal investigators in her regularLate… View more

Anticoagulation

Vascular Disease and Surgery